> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Duavee
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-duavee/
- Published: 2018-02-02T12:00:00.000Z
- Updated: 2026-09-14T23:19:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140667

*Federal Register* notice: FDA has determined for patent extension purposes that the regulatory review period for Duavee (conjugated estrogens/bazedoxifene acetate) is 5,683 days. Of this time, 5,317 days occurred during the testing phase and 366 days during the approval phase. Duavee is indicated for treating moderate to severe vasomotor symptoms associated with menopause, and preventing postmenopausal osteoporosis. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-31/pdf/2018-01894.pdf?ref=fdaweb.com).